JP2012520249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520249A5 JP2012520249A5 JP2011553352A JP2011553352A JP2012520249A5 JP 2012520249 A5 JP2012520249 A5 JP 2012520249A5 JP 2011553352 A JP2011553352 A JP 2011553352A JP 2011553352 A JP2011553352 A JP 2011553352A JP 2012520249 A5 JP2012520249 A5 JP 2012520249A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- urinary incontinence
- epilepsy
- mania
- migraine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims description 10
- 206010046543 Urinary incontinence Diseases 0.000 claims description 9
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 206010026749 Mania Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 206010012335 Dependence Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- -1 3-chloro-2-hydroxypropylthio Chemical group 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- CKWKREFECQVBBZ-UHFFFAOYSA-N 2-sulfanylidene-1h-quinoline-3-carboxamide Chemical class C1=CC=C2N=C(S)C(C(=O)N)=CC2=C1 CKWKREFECQVBBZ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 1
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 description 1
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
Description
さらに、ＫＣＮＱ２／３Ｋ＋チャンネルは、多数の他の疾患、例えば偏頭痛（米国特許第２００２／０１２８２７７号明細書）、認識疾患（Ｇｒｉｂｋｏｆｆ著， Ｅｘｐｅｒｔ Ｏｐｉｎ Ｔｈｅｒ Ｔａｒｇｅｔｓ ２００３； ７（６）： ７３７−７４８）、不安状態（Ｋｏｒｓｇａａｒｄ ｅｔ ａｌ．著， Ｊ Ｐｈａｒｍａｃｏｌ Ｅｘｐ Ｔｈｅｒ． ２００５， １４（１）： ２８２−９２）、てんかん（Ｗｉｃｋｅｎｄｅｎ ｅｔ ａｌ．著， Ｅｘｐｅｒｔ Ｏｐｉｎ Ｔｈｅｒ Ｐａｔ ２００４， １４（４）： ４５７−４６９； Ｇｒｉｂｋｏｆｆ著， Ｅｘｐｅｒｔ Ｏｐｉｎ Ｔｈｅｒ Ｔａｒｇｅｔｓ ２００８， １２（５）： ５６５−８１； Ｍｉｃｅｌｉ ｅｔ ａｌ．著， Ｃｕｒｒ Ｏｐｉｎ Ｐｈａｒｍａｃｏｌ ２００８， ８（１）： ６５−７４）、尿失禁（Ｓｔｒｅｎｇ ｅｔ ａｌ．著， Ｊ Ｕｒｏｌ ２００４；１７２： ２０５４−２０５８）、依存症（Ｈａｎｓｅｎ ｅｔ ａｌ．著， Ｅｕｒ Ｊ Ｐｈａｒｍａｃｏｌ ２００７， ５７０（１−３）： ７７−８８）、躁病／双極性障害（Ｄｅｎｃｋｅｒ ｅｔ ａｌ．著， Ｅｐｉｌｅｐｓｙ Ｂｅｈａｖ ２００８， １２（１）： ４９−５３）、筋失調に関連する運動障害（Ｒｉｃｈｔｅｒ ｅｔ ａｌ．著， Ｂｒ Ｊ Ｐｈａｒｍａｃｏｌ ２００６， １４９（６）： ７４７−５３）の治療のための適当な対象である。
有利に、本発明による医薬は、痛み、有利に急性痛、慢性痛、神経障害性痛、筋肉性痛及び炎症性痛からなる群から選択される痛み；てんかん、尿失禁、不安状態、依存症、躁病、双極性障害、偏頭痛、認識疾患、筋失調と関連する運動障害及び／又は尿失禁からなる群から選択される１種又は数種の疾患の治療のために適している。
痛み、有利に急性痛、慢性痛、神経障害性痛、筋肉性痛及び炎症性痛から選択される痛み；てんかん、尿失禁、不安状態、依存症、躁病、双極性障害、偏頭痛、認識障害、筋失調と関連する運動障害及び／又は尿失禁を治療するための医薬を製造するための、少なくとも１種の本発明による置換された２−メルカプトキノリン−３−カルボキサミド並びに場合により１種若しくは数種の製剤学的に許容された助剤の使用が有利である。
本発明の他の主題は、痛み、有利に急性痛、慢性痛、神経障害性痛、筋肉性痛及び炎症性痛から選択される痛み；てんかん、尿失禁、不安状態、依存症、躁病、双極性障害、偏頭痛、認識障害、筋失調と関連する運動障害及び／又は尿失禁を治療するための、少なくとも１種の本発明による置換された２−メルカプトキノリン−３−カルボキサミド並びに場合により１種若しくは数種の製剤学的に許容された助剤である。
Claims (1)
- 痛み、てんかん、尿失禁、不安状態、依存症、躁病、双極性障害、偏頭痛、認識障害、筋失調と関連する運動障害及び／又は尿失禁の治療のための医薬を製造するための、それぞれ個々の立体異性体又はその混合物、遊離化合物及び／又はその生理学的に許容される塩の形態での請求項１から１３のいずれか一項に記載の少なくとも１種の置換されたカルボキサミド又はＮ−ベンジル−２−（３−クロロ−２−ヒドロキシプロピルチオ）−４−（２，４−ジクロロフェニル）キノリン−３−カルボキサミドの化合物の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09003597.3 | 2009-03-12 | ||
| EP09003597 | 2009-03-12 | ||
| PCT/EP2010/001509 WO2010102811A1 (de) | 2009-03-12 | 2010-03-11 | Substituierte 2-mercaptochinolin-3-carboxamide als kcnq2/3 modulatoren |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520249A JP2012520249A (ja) | 2012-09-06 |
| JP2012520249A5 true JP2012520249A5 (ja) | 2014-10-16 |
| JP5727946B2 JP5727946B2 (ja) | 2015-06-03 |
Family
ID=40671387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553352A Expired - Fee Related JP5727946B2 (ja) | 2009-03-12 | 2010-03-11 | Ｋｃｎｑ２／３モジュレータとしての置換された２−メルカプトキノリン−３−カルボキサミド |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20100234372A1 (ja) |
| EP (1) | EP2406229A1 (ja) |
| JP (1) | JP5727946B2 (ja) |
| KR (1) | KR20110132590A (ja) |
| CN (1) | CN102348692A (ja) |
| AR (1) | AR075824A1 (ja) |
| AU (1) | AU2010223513B2 (ja) |
| BR (1) | BRPI1008939A2 (ja) |
| CA (1) | CA2755004A1 (ja) |
| CL (1) | CL2011002209A1 (ja) |
| CO (1) | CO6410292A2 (ja) |
| EC (1) | ECSP11011348A (ja) |
| IL (1) | IL214945A0 (ja) |
| MX (1) | MX2011009369A (ja) |
| NZ (1) | NZ595625A (ja) |
| PE (1) | PE20120790A1 (ja) |
| RU (1) | RU2011141188A (ja) |
| TW (1) | TWI461197B (ja) |
| WO (1) | WO2010102811A1 (ja) |
| ZA (1) | ZA201107444B (ja) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3178067B2 (ja) | 1991-02-26 | 2001-06-18 | ぺんてる株式会社 | スズ−ニッケル二元合金電気めっき液組成物 |
| MX2011008825A (es) * | 2009-03-10 | 2011-09-21 | Gruenenthal Gmbh | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. |
| TWI504395B (zh) * | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
| TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
| SI2609086T1 (sl) | 2010-08-27 | 2015-04-30 | Gruenenthal Gmbh | Substituirani 2-okso in 2-tiokso-dihidrokinolin-3-karboksamidi kot KCNQ2/3 modulatorji |
| BR112013004562A2 (pt) | 2010-08-27 | 2016-09-06 | Gruenenthal Gmbh | 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3 |
| MX2013002295A (es) | 2010-09-01 | 2013-05-09 | Gruenenthal Gmbh | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
| WO2014056620A1 (en) | 2012-10-11 | 2014-04-17 | Grünenthal GmbH | Treatment and/or prophylaxis of tspo mediated diseases and/or disorders |
| CA2892745A1 (en) | 2012-11-28 | 2014-06-05 | Grunenthal Gmbh | Specific carboxamides as kcnq2/3 modulators |
| WO2014082738A1 (en) | 2012-11-28 | 2014-06-05 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as kcnq2/3 modulators |
| US9248122B2 (en) | 2012-11-28 | 2016-02-02 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as KCNQ2/3 modulators |
| EP2951168B1 (en) * | 2013-01-31 | 2017-01-04 | Vertex Pharmaceuticals Incorporated | Quinoline and quinoxaline amides as modulators of sodium channels |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| JP2016511237A (ja) | 2013-02-01 | 2016-04-14 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 選択的ｈｄａｃ３阻害剤 |
| JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| WO2014130612A1 (en) | 2013-02-20 | 2014-08-28 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CN108530458A (zh) | 2013-11-01 | 2018-09-14 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| PH12015000236B1 (en) * | 2015-07-06 | 2024-01-10 | Samsung Electronics Co Ltd | Electronic device for providing a calibrated keyboard configuration |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| JP7120549B2 (ja) | 2016-12-15 | 2022-08-17 | 小野薬品工業株式会社 | Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ |
| DE102018212006B3 (de) | 2018-07-18 | 2019-10-31 | Universität Greifswald | Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen |
| JP2025529185A (ja) * | 2022-08-30 | 2025-09-04 | パンネックス セラピューティクス インコーポレイテッド | パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2706977A1 (de) | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
| FR2532939A1 (fr) * | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
| DE4032147A1 (de) | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
| EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
| WO1996026925A1 (en) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Arylthioacetamide derivatives |
| DE19738615A1 (de) * | 1997-09-04 | 1999-03-11 | Clariant Gmbh | Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen |
| DE19738616A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel |
| AU3033500A (en) * | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| US6326385B1 (en) | 1999-08-04 | 2001-12-04 | Icagen, Inc. | Methods for treating or preventing pain |
| WO2001010380A2 (en) | 1999-08-04 | 2001-02-15 | Icagen, Inc. | Benzanilides as potassium channel openers |
| HUP0303841A2 (hu) | 2001-02-20 | 2004-03-01 | Bristol-Myers Squibb Company | 2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk |
| US6855829B2 (en) * | 2001-02-20 | 2005-02-15 | Bristol-Myers Squibb Company | 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease |
| US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| JP2004526756A (ja) * | 2001-04-06 | 2004-09-02 | スミスクライン ビーチャム コーポレーション | ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤 |
| US20040110947A1 (en) | 2002-09-17 | 2004-06-10 | Pharmacia Corporation | Aromatic liver X-receptor modulators |
| CA2505195C (en) | 2002-12-23 | 2012-07-10 | Icagen, Inc. | Quinazolinones as potassium channel modulators |
| EP1449841A1 (en) | 2003-02-19 | 2004-08-25 | Bayer CropScience SA | New fungicidal compounds |
| US7598412B2 (en) | 2003-10-08 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| JP4054369B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | オルト置換アリールまたはヘテロアリールアミド化合物 |
| NZ587549A (en) * | 2004-06-24 | 2012-10-26 | Vertex Pharma | 6-Amino-indole derivatives and processes for their preparation |
| EP1814856A1 (en) | 2004-11-12 | 2007-08-08 | Galapagos N.V. | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| WO2006092143A1 (en) | 2005-03-03 | 2006-09-08 | H. Lundbeck A/S | Substituted pyridine derivatives |
| DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| DE602006007012D1 (de) | 2005-07-20 | 2009-07-09 | Lilly Co Eli | Pyridinderivate als dipeptedyl-peptidase-hemmer |
| WO2007030582A2 (en) | 2005-09-09 | 2007-03-15 | Bristol-Myers Squibb Company | Acyclic ikur inhibitors |
| WO2007057447A1 (en) | 2005-11-18 | 2007-05-24 | Neurosearch A/S | Novel quinazoline derivatives and their medical use |
| DE602007004638D1 (de) | 2006-07-20 | 2010-03-18 | Amgen Inc | Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin |
| CA2658190C (en) | 2006-07-20 | 2013-01-29 | Amgen Inc. | Di-amino-substituted heterocyclic compounds and methods of use |
| WO2008012532A2 (en) | 2006-07-27 | 2008-01-31 | Astrazeneca Ab | : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
| BRPI0719590A2 (pt) * | 2006-11-28 | 2014-01-21 | Valeant Pharmaceuticals Int | Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| JP5341084B2 (ja) | 2007-08-03 | 2013-11-13 | エフ．ホフマン−ラ ロシュ アーゲー | Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
| CA2702469A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Ccr10 antagonists |
| MX2011008825A (es) * | 2009-03-10 | 2011-09-21 | Gruenenthal Gmbh | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. |
| TWI504395B (zh) * | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
| TW201038565A (en) * | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
| TWI475020B (zh) * | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier |
-
2010
- 2010-02-24 TW TW099105238A patent/TWI461197B/zh not_active IP Right Cessation
- 2010-03-10 US US12/720,864 patent/US20100234372A1/en not_active Abandoned
- 2010-03-11 EP EP10708726A patent/EP2406229A1/de not_active Withdrawn
- 2010-03-11 CN CN2010800112967A patent/CN102348692A/zh active Pending
- 2010-03-11 KR KR1020117023788A patent/KR20110132590A/ko not_active Withdrawn
- 2010-03-11 PE PE2011001567A patent/PE20120790A1/es not_active Application Discontinuation
- 2010-03-11 AU AU2010223513A patent/AU2010223513B2/en not_active Ceased
- 2010-03-11 BR BRPI1008939A patent/BRPI1008939A2/pt not_active IP Right Cessation
- 2010-03-11 CA CA2755004A patent/CA2755004A1/en not_active Abandoned
- 2010-03-11 RU RU2011141188/04A patent/RU2011141188A/ru not_active Application Discontinuation
- 2010-03-11 JP JP2011553352A patent/JP5727946B2/ja not_active Expired - Fee Related
- 2010-03-11 MX MX2011009369A patent/MX2011009369A/es active IP Right Grant
- 2010-03-11 NZ NZ595625A patent/NZ595625A/xx not_active IP Right Cessation
- 2010-03-11 WO PCT/EP2010/001509 patent/WO2010102811A1/de not_active Ceased
- 2010-03-12 AR ARP100100777A patent/AR075824A1/es not_active Application Discontinuation
-
2011
- 2011-08-24 CO CO11107978A patent/CO6410292A2/es not_active Application Discontinuation
- 2011-09-04 IL IL214945A patent/IL214945A0/en unknown
- 2011-09-08 CL CL2011002209A patent/CL2011002209A1/es unknown
- 2011-09-23 EC EC2011011348A patent/ECSP11011348A/es unknown
- 2011-10-11 ZA ZA2011/07444A patent/ZA201107444B/en unknown
-
2012
- 2012-06-15 US US13/523,955 patent/US8399673B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520249A5 (ja) | ||
| JP2012521966A5 (ja) | ||
| JP2018513107A5 (ja) | ||
| JP2009510044A5 (ja) | ||
| JP2014506321A5 (ja) | ||
| CA2676456A1 (en) | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof | |
| EA201390827A1 (ru) | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом | |
| JP2009533356A5 (ja) | ||
| JP2017528507A5 (ja) | ||
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| JP2013139446A5 (ja) | ||
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| JP2010529118A5 (ja) | ||
| JP2009504622A5 (ja) | ||
| JP2015523321A5 (ja) | ||
| RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2015535270A5 (ja) | ||
| JP2016540749A5 (ja) | ||
| JP2016522254A5 (ja) | ||
| JP7167236B2 (ja) | せん妄の予防または治療剤 | |
| JP2016501219A5 (ja) | ||
| JP2013506003A5 (ja) | ||
| JP2009513604A5 (ja) | ||
| JP2014511897A5 (ja) | ||
| JP2013516475A5 (ja) |